Researchers have shown the key role that a protein called Ran plays in the mobility of ovarian cancer cells. They demonstrated these cells cannot migrate from cancerous sites without the help of Ran.

A special blood test may one day predict if a newly diagnosed breast cancer patient will likely relapse years later, a City of Hope study suggests.

High-grade serous ovarian cancer (HGSOC) is the most common and aggressive subtype of ovarian cancer. The HGSOC tumours consist of several heterogeneous cell populations with a large number of mutations. This genetic variability makes it difficult to find drugs that would kill all the cancer cells, and to which the cells would not become resistant during treatment. Over half of the patients diagnosed with high-grade serous ovarian cancer die within five years of diagnosis, that is, annually more than 150 000 women globally.

Cervical cancer is a major issue in low- and middle-income countries due to the lack of adequate screening such as routine Pap smear testing. These countries have high incidences of cervical cancer linked to human papillomavirus (HPV). Due to lack of resources for cancer screenings, these countries account for 85 percent of all cervical cancer cases.

A team of researchers has discovered an unexpected relationship between levels of the amino acid leucine and the development of tamoxifen resistance in ER breast cancer.

Cervical cancer negative for the human papilloma virus (HPV) is rare but more aggressive: it is more frequently diagnosed at advanced stages, with more metastasis and reduced survival. These conclusions are published in Modern Pathology. The study was co-led by ISGlobal, an institution supported by “la Caixa”, the Hospital Clinic and the University of Barcelona.